Ocugen (OCGN) Competitors $0.76 +0.03 (+3.64%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$0.76 0.00 (-0.52%) As of 05/2/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. BCAX, AVXL, CMRX, CDMO, DAWN, OCS, CVAC, ABCL, RCKT, and LENZShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Bicara Therapeutics (BCAX), Anavex Life Sciences (AVXL), Chimerix (CMRX), Avid Bioservices (CDMO), Day One Biopharmaceuticals (DAWN), Oculis (OCS), CureVac (CVAC), AbCellera Biologics (ABCL), Rocket Pharmaceuticals (RCKT), and LENZ Therapeutics (LENZ). These companies are all part of the "pharmaceutical products" industry. Ocugen vs. Bicara Therapeutics Anavex Life Sciences Chimerix Avid Bioservices Day One Biopharmaceuticals Oculis CureVac AbCellera Biologics Rocket Pharmaceuticals LENZ Therapeutics Ocugen (NASDAQ:OCGN) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings. Do insiders & institutionals believe in OCGN or BCAX? 10.3% of Ocugen shares are owned by institutional investors. 4.3% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer OCGN or BCAX? Ocugen presently has a consensus target price of $6.33, indicating a potential upside of 727.89%. Bicara Therapeutics has a consensus target price of $32.43, indicating a potential upside of 123.66%. Given Ocugen's stronger consensus rating and higher probable upside, analysts clearly believe Ocugen is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Bicara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Does the media refer more to OCGN or BCAX? In the previous week, Bicara Therapeutics had 8 more articles in the media than Ocugen. MarketBeat recorded 16 mentions for Bicara Therapeutics and 8 mentions for Ocugen. Bicara Therapeutics' average media sentiment score of 1.06 beat Ocugen's score of 0.52 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocugen 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is OCGN or BCAX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -532.51%. Bicara Therapeutics' return on equity of 0.00% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-532.51% -154.75% -90.79% Bicara Therapeutics N/A N/A N/A Which has stronger valuation & earnings, OCGN or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than Ocugen. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$4.06M55.09-$63.08M-$0.19-4.03Bicara TherapeuticsN/AN/AN/AN/AN/A Does the MarketBeat Community prefer OCGN or BCAX? Ocugen received 99 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 87.50% of users gave Bicara Therapeutics an outperform vote while only 71.07% of users gave Ocugen an outperform vote. CompanyUnderperformOutperformOcugenOutperform Votes11371.07% Underperform Votes4628.93% Bicara TherapeuticsOutperform Votes1487.50% Underperform Votes212.50% SummaryBicara Therapeutics beats Ocugen on 8 of the 14 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$223.39M$2.97B$5.55B$8.02BDividend YieldN/A1.87%5.09%4.22%P/E Ratio-4.2530.5222.6918.83Price / Sales55.09494.70404.28106.72Price / CashN/A168.6838.1834.62Price / Book4.783.216.794.33Net Income-$63.08M-$72.35M$3.22B$247.97M7 Day Performance6.37%13.48%3.38%3.18%1 Month Performance19.77%12.33%6.96%8.13%1 Year Performance-42.48%-23.51%16.13%5.01% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.0046 of 5 stars$0.77+3.6%$6.33+727.9%-42.0%$223.39M$4.06M-4.2580News CoverageBCAXBicara TherapeuticsN/A$14.85+2.1%$32.43+118.5%N/A$816.05MN/A0.0032Analyst RevisionNews CoveragePositive NewsGap DownAVXLAnavex Life Sciences3.837 of 5 stars$9.54+1.3%$44.00+361.2%+148.9%$814.49MN/A-17.4140Upcoming EarningsNews CoveragePositive NewsCMRXChimerix2.9018 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212,000.00-9.0990Analyst ForecastCDMOAvid Bioservices0.7324 of 5 stars$12.50+0.1%$12.25-2.0%+52.4%$799.18M$139.91M-5.23320High Trading VolumeDAWNDay One Biopharmaceuticals2.4078 of 5 stars$7.69-0.7%$32.29+320.1%-54.9%$780.93M$131.16M-7.4860Upcoming EarningsNews CoveragePositive NewsOCSOculis2.769 of 5 stars$17.70+4.1%$30.25+70.9%+46.1%$775.22M$980,000.00-9.202News CoverageCVACCureVac3.8606 of 5 stars$3.45+6.7%$16.00+364.4%+28.5%$774.42M$535.18M6.28880Analyst ForecastABCLAbCellera Biologics2.4107 of 5 stars$2.59+0.6%$7.50+190.1%-37.4%$773.28M$28.83M-4.25500Upcoming EarningsRCKTRocket Pharmaceuticals4.6626 of 5 stars$7.10-1.9%$43.00+506.1%-64.8%$759.74MN/A-2.59240Upcoming EarningsLENZLENZ Therapeutics1.9984 of 5 stars$27.44+2.1%$46.60+69.8%+79.9%$754.95MN/A-5.75110News CoveragePositive News Related Companies and Tools Related Companies Bicara Therapeutics Alternatives Anavex Life Sciences Alternatives Chimerix Alternatives Avid Bioservices Alternatives Day One Biopharmaceuticals Alternatives Oculis Alternatives CureVac Alternatives AbCellera Biologics Alternatives Rocket Pharmaceuticals Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThe collapse has already startedThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OCGN Stock Free OCGN Stock Alerts